🌍·3d agoIndustry
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Publisher
M
Matinas BioPharma
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on matinasbiopharma.com
Leave the platform to read the original full article on the publisher site.
Source: Matinas BioPharma
Scope: Industry
Related coverage
More related coverage
Tempus·20h ago
The multimodal imperative: Leveraging integrated data streams to accelerate oncology research and drug development
PeptiDream·1d ago
2026.04.06æ ªä¸»ç ä¼ã®Q&Aãå ¬éãã¾ãã
IDEAYA Biosciences·1d ago
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low...
Agios Pharmaceuticals·1d ago